|
PAION AG / Key word(s): Change in Forecast PAION AG cancelled guidance for financial year 2023 24-Nov-2023 / 13:46 CET/CEST Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by EQS News – a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. PAION AG cancelled guidance for financial year 2023 Aachen (Germany), 24 November 2023 – The specialty pharma company PAION AG (ISIN DE000A3E5EG5; Frankfurt Stock Exchange, PA8) announces that against the background of the applications filed for the opening of insolvency proceedings, the forecast for the current financial year 2023 previously issued on 17 May 2023 in connection with the publication of the annual financial report can no longer be maintained and is therefore canceled. Due to the preliminary insolvency proceedings and the unforeseeable further development, it is also currently not possible to issue a new forecast. End of Inside Information Information and Explanation of the Issuer to this announcement: Contact Ralf Penner SVP Investor Relations & Corporate Communications PAION AG Heussstrasse 25 52078 Aachen – Germany Phone +49 241 4453-152 E-mail r.penner@paion.com www.paion.com Disclaimer: This release contains certain forward-looking statements concerning the future business of PAION AG. These forward-looking statements contained herein are based on the current expectations, estimates and projections of PAION AG’s management as of the date of this release. They are subject to a number of assumptions and involve known and unknown risks, uncertainties and other factors. Should actual conditions differ from PAION AG’s assumptions, actual results and actions may differ materially from any future results and developments expressed or implied by such forward-looking statements. Considering the risks, uncertainties and other factors involved, recipients should not rely unreasonably upon these forward-looking statements. PAION AG has no obligation to periodically update any such forward-looking statements to reflect future events or developments. 24-Nov-2023 CET/CEST The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. |
Nuvation inks all-stock deal for US-China oncology biotech AnHeart
Nuvation Bio plans to buy AnHeart Therapeutics in an all-stock deal, the cancer drug developers said Monday morning, in a move that could turn Nuvation
March 26, 2024